

## Segra International completes first export of *Cannabis* plantlets from Canada to the USA

VANCOUVER, June 29, 2021 — Segra International Corp, a leading cannabis agriculture technology company, is pleased to announce its first successful export of Verified Segra Stock™ *Cannabis* plantlets to the Biopharmaceutical Research Company (BRC), one of the first groups in the USA to receive approval from the DEA to cultivate *Cannabis* for scientific research purposes.

This shipment marks a tremendous milestone in the evolution of the US cannabis industry, as it represents one of the first imports of live *Cannabis* plants to a federally licensed US cultivator. In recent months, the DEA has issued a select number of licenses to several groups in the US to allow for the cultivation of *Cannabis* for scientific research purposes. BRC, based in California, is among the first companies granted a license and is now operational. Segra's Verified Segra Stock™ plantlets will provide BRC with standardized and validated starting materials produced through plant tissue culture and backed by extensive agronomic data and *Cannabis* plant pathogen screening.

BRC works with research groups studying *Cannabis* and *Cannabis* flower to understand the plant in a scientific and federally regulated environment. Under the federal licensing regime, BRC is only allowed to source genetics and starting material from DEA-compliant or federally legal sources.

"Segra's Verified Segra Stock™ guarantee means our plantlets are DNA fingerprinted and pathogen-free with virtually no risk of pathogen introduction to the receiving grow facility. Starting with this input material is critical to effectively grow replicable crops, something highly valued by researchers who are studying the finished product of the *Cannabis* plant and its derivatives," said Jamie Blundell, CEO of Segra International. "Furthermore, Segra's VNTR DNA Fingerprinting technology allows BRC to order plantlets and cultivars with certainty, knowing they are receiving the same input material with each shipment. The application of VNTR DNA fingerprinting technology can be used throughout the supply chain for track and trace purposes, from plantlet to flower, translating this certainty to researchers who can study the same product repeatedly."

"At BRC, we are focused on developing federally compliant active pharmaceutical ingredients for federally compliant researchers examining the therapeutic effects of *Cannabis*" said George Hodgins, CEO of Biopharmaceutical Research Company. "We're fortunate to be working with Segra to offer our clients a wide range of clean, high-quality *Cannabis* of specific chemical expressions and flower types to help them better understand the applications of the *Cannabis* plant."

Learn more about Segra's services and premium cultivars by viewing the [2021 Cultivar and Services Catalogue](#).

### **About Segra:**

Segra is an agriculture technology company offering plant tissue culture, plant genomics, and pathogen detection services to accelerate the advancement of the cannabis industry. The company's proprietary technologies empower its clients to drive financial performance and mitigate risk while exploring the next frontier of optimized cultivation practices for the rapidly evolving cannabis consumer. Segra has developed industrial-scale laboratories to produce Verified Segra Stock™, robust, and DNA-fingerprinted *Cannabis* plantlets for licensed producers globally. Segra has assembled a world-class team of specialists in agronomy, molecular genetics, plant tissue culture, and regulatory compliance to support this vision. Learn more at [segra-intl.com](http://segra-intl.com) or by viewing the [2021 Cultivar and Services Catalogue](#).

**About Biopharmaceutical Research Company**

**BRC is a specialty pharmaceutical company that holds several DEA Registrations across the entire value chain of *Cannabis* and is pioneering the federally legal *Cannabis* space in the USA.**

**For Further Information:**

Carson Otto

[Carson.otto@segra-intl.com](mailto:Carson.otto@segra-intl.com)

**Forward-Looking Information:**

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except

-